Scientists at St. Jude Children’s Research Hospital found that tumor cells use LINE-1 retrotransposons to restructure the genome to promote cancer gene expression.

With nearly $1 million in federal funding, a University of Houston researcher will study the connection between an enzyme found in cancerous tumors and immune cells of lupus patients — innovative research that could transform how lupus is diagnosed and treated.

Removing part or all of the breast during breast cancer treatment is a potential outcome for some people. Reconstructive surgical procedures often involve prosthetic implants or transplanted tissue from elsewhere in the body. So, researchers reporting in ACS Applied Bio Materials developed a prototype injectable paste derived from human skin cells that could help restore breast volume after tumor removal, with less scarring and shorter healing time than current options.

The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance A032304) to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer. The Alliance for Clinical Trials in Oncology has launched a randomized phase III clinical trial called RECIPROCAL (Alliance A032304) to explore whether doctors can optimize the timing of targeted radiation therapy to minimize side effects while preserving efficacy in men with advanced prostate cancer.

In the current study, published today in the journal Nature Biotechnology, Cheng and his colleagues created an exosome system that co-displays two therapeutic proteins to treat lung metastases. One protein blocks the PD-1/PD-L1 immune checkpoint pathway, a process that has been shown to boost the immune response against melanoma cells and shrink tumors. The other protein blocks the Wnt/β-catenin signaling pathway that drives immune exclusion in tumors, a phenomenon where immune cells are unable to infiltrate tumor tissues. 

A large-scale international study, led by researchers from the Gray Faculty of Medical and Health Sciences at Tel Aviv University, has uncovered a mechanism that allows breast cancer to send metastases to the brain — a highly lethal occurrence for which there is currently no effective treatment. The findings could enable the development of new drugs and personalized monitoring for early detection and treatment of brain metastases.

This study reveals how lipid metabolism dysregulation promotes colorectal cancer liver metastasis (CRLM) through a novel YTHDF3-mediated mechanism involving m⁶A RNA modification and liquid-liquid phase separation.